Search Results
Jan 07, 2026, 11:00 ET Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC) for the treatment of pancreatic cancer. ARB1002 is composed of an anti-CDH17 monoclonal antibody chemically linked to a potent cytotoxic agent. The ADC is designed to selectively bind CDH17, a cell-surface adhesion molecule
More news about: Arbele
Jan 07, 2026, 07:00 ET Xtalks Announces its Life Science Webinar Calendar for January 2026
Depressive Disorder Clinical TrialsJan 28 - How to Reduce Eligibility Risk and Prevent Protocol DeviationsJan 29 - Operationalizing ADC Clinical Trials: Best Practices for SuccessDRUG DISCOVERY & DEVELOPMENTJan 14 - Bioassay Method Transfer Strategies to Reduce
More news about: Xtalks
Jan 07, 2026, 03:30 ET Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license
More news about: Synaffix
Jan 06, 2026, 21:44 ET Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-biotech
Jan 06, 2026, 20:00 ET 晶泰科技賦能國內首個「AI + RNA」小分子創新藥獲批臨床，ReviR溪礫科技實現罕見病首創新藥突破
罕見病藥物研發領域的先進實踐，其在國內臨床的推進，有利於重塑罕見病治療的公平性，並在角逐全球高淨值市場中體現中國技術力量。作為港股 「AI4Science（科學智能）」、「AI +機器人」 第一股，晶泰科技憑借 「量子物理+AI+大規模機器人實驗」 的獨特技術閉環，構建起行業領先的標準化、自動化研發基礎設施與智能藥物研發平台，橫跨小分子、抗體、多肽、ADC、分子膠等多種藥物形態，具備了規模化輸出能力，已獲得全球前 20 大藥企中 17 家的長期合作與信賴。區別於自建管線的 AI 驅動型藥企與生物科技公司，晶泰科技通過平台化商業模式持續孵化創新管線：一方面為合作夥伴提供 「從 0 到 1」 的創新突破並獲取里程碑付款，另一方面通
More news about: 晶泰科技
Jan 06, 2026, 08:00 ET Unchained Labs Cracks the Code on ADC Characterization
researchers the right tool for the job, just launched a brand-new application on Stunner today that delivers rapid, low-volume antibody-drug conjugate (ADC) characterization on up to 96 samples at a time.
More news about: Unchained Labs
Jan 06, 2026, 08:00 ET Unchained Labs Cracks the Code on ADC Characterization
researchers the right tool for the job, just launched a brand-new application on Stunner today that delivers rapid, low-volume antibody-drug conjugate (ADC) characterization on up to 96 samples at a time.
More news about: Unchained Labs
Jan 06, 2026, 06:30 ET MulticoreWare Announces Plans to Join Qualcomm Authorized Design Center Program to Accelerate AI Scaling and Productization
intelligence (AI) solutions, today announced its intended collaboration with Qualcomm Technologies, Inc. to serve as an AI Software Authorized Design Center (ADC).
More news about: MulticoreWare Inc.
Jan 05, 2026, 07:00 ET Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
Jan 05, 2026, 07:00 ET 科倫博泰ITGB6 ADC SKB105臨床試驗申請獲NMPA批准
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/itgb6-adc-skb105nmpa-302652401.htmlSOURCE 科倫博泰
More news about: 科倫博泰
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
Jan 02, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Dec 30, 2025, 02:00 ET Tanmiah Champions Local Excellence with the Launch of a New Breaded Chicken Range, Produced Using Only 100% Fresh Saudi Chicken
a cup of vegetables per pack. Another notable addition is a product inspired by bold, trending KOREAN cuisine.Marcos Delorenzo, CEO of ADC (Tanmiah's Poultry Division), added: "Our new breaded chicken range is the result of a robust development journey. We listened closely to Saudi consumers
More news about: Tanmiah Food Company
Dec 30, 2025, 02:00 ET Tanmiah Champions Local Excellence with the Launch of a New Breaded Chicken Range, Produced Using Only 100% Fresh Saudi Chicken
a cup of vegetables per pack. Another notable addition is a product inspired by bold, trending KOREAN cuisine.Marcos Delorenzo, CEO of ADC (Tanmiah's Poultry Division), added: "Our new breaded chicken range is the result of a robust development journey. We listened closely to Saudi consumers
More news about: Tanmiah Food Company
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
breakthrough therapies, capture a substantial share of the rapidly growing ADC market, and build a diverse oncology treatment platform. The company reiterated its commitment to strengthening its R&D pipeline, integrating next-generation ADC technologies with its proprietary drug candidates, and advancing toward
More news about: Senhwa Biosciences, Inc.
Dec 25, 2025, 23:47 ET ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programs."Meanwhile, on November 12 and 14, ABL Bio signed a license, research and collaboration agreement for Grabody platform with Lilly valued
More news about: ABL Bio, Inc.
Dec 25, 2025, 23:38 ET ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programs."Meanwhile, on November 12 and 14, ABL Bio signed a license, research and collaboration agreement for Grabody platform with Lilly valued
More news about: ABL Bio, Inc.
Dec 24, 2025, 08:54 ET El consejero delegado de Henlius, Dr. Jason Zhu, realizará una presentación magistral en JPM 2026
sobre la innovadora línea de productos de la compañía y las plataformas tecnológicas de última generación, incluyendo conjugados anticuerpo-fármaco (ADC) y activadores multiespecíficos de células T (TCE), y presentará la perspectiva estratégica de Henlius para los próximos cinco años. Aprovechando una
More news about: Henlius
Dec 21, 2025, 20:00 ET Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a
More news about: Fosun
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Mohamed Zaki, MD, PhD, CMO of ADC Therapeutics. "We are well on the way to completing enrollment of approximately 100 patients at the selected dose and plan to share full results at a medical congress and through a publication by the end of next year."ADC Therapeutics expects to complete
More news about: Equity Insider
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
clinicaltrials.gov.About PADCEV™ (enfortumab vedotin) PADCEV™ (enfortumab vedotin) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.vii Nonclinical data
More news about: Astellas Pharma Inc.
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA
More news about: Antengene Corporation Limited
Dec 16, 2025, 19:19 ET Allink Biotherapeutics completa rondas de extensión de la Serie A por 47 millones de dólares
existentes.Los fondos se destinarán al avance de dos programas de ADC diferenciados y altamente competitivos en ensayos globales de Fase I.La financiación apoyará el desarrollo continuo de ADC y plataformas de anticuerpos multiespecíficos, destinadas a abordar las limitaciones
More news about: Allink Biotherapeutics
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
https://www.targetedonc.com/view/fda-fast-tracks-novel-adc-in-pancreatic-cancer2.
More news about: USA News Group